These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 29360527)
1. Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology. Crescioli S; Chiaruttini G; Mele S; Ilieva KM; Pellizzari G; Spencer DIR; Gardner RA; Lacy KE; Spicer JF; Tutt ANJ; Wagner GK; Karagiannis SN J Allergy Clin Immunol; 2018 Apr; 141(4):1519-1523.e9. PubMed ID: 29360527 [No Abstract] [Full Text] [Related]
2. The nascent field of AllergoOncology. Jensen-Jarolim E; Pawelec G Cancer Immunol Immunother; 2012 Sep; 61(9):1355-7. PubMed ID: 22911119 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of immunotherapy with allergoids: lessons for the development of recombinant allergens with reduced IgE-binding activity. Cromwell O; Kahlert H; Schramm G; Suck R; Nandy A; Weber B; Fiebig H Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):156-61; discussion 161-2. PubMed ID: 15119034 [No Abstract] [Full Text] [Related]
12. Cross-reaction of recombinant termite (Coptotermes formosanus) tropomyosin with IgE from cockroach and shrimp allergic individuals. Vargas AM; Mahajan A; Tille KS; Wilson BS; Mattison CP Ann Allergy Asthma Immunol; 2018 Mar; 120(3):335-337. PubMed ID: 29508724 [No Abstract] [Full Text] [Related]
13. Passive immunization with allergen-specific antibodies. Flicker S; Gadermaier E; Madritsch C; Valenta R Curr Top Microbiol Immunol; 2011; 352():141-59. PubMed ID: 21681684 [TBL] [Abstract][Full Text] [Related]
14. Renaissance of the blocking antibody concept in type I allergy. Flicker S; Valenta R Int Arch Allergy Immunol; 2003 Sep; 132(1):13-24. PubMed ID: 14555854 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T-cells specific for natural IgE peptides downregulate IgE production. Chen SS; Gong J; Yang YM; Oettgen H; Zanetti M Cell Immunol; 2005 Jan; 233(1):11-22. PubMed ID: 15913585 [TBL] [Abstract][Full Text] [Related]
16. Clinical experience with recombinant molecules for allergy vaccination. Cromwell O; Niederberger V; Horak F; Fiebig H Curr Top Microbiol Immunol; 2011; 352():27-42. PubMed ID: 21562972 [TBL] [Abstract][Full Text] [Related]
17. AllergoOncology: the role of IgE-mediated allergy in cancer. Jensen-Jarolim E; Achatz G; Turner MC; Karagiannis S; Legrand F; Capron M; Penichet ML; Rodríguez JA; Siccardi AG; Vangelista L; Riemer AB; Gould H Allergy; 2008 Oct; 63(10):1255-66. PubMed ID: 18671772 [TBL] [Abstract][Full Text] [Related]
18. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Asturias JA; Ibarrola I; Arilla MC; Vidal C; Ferrer A; Gamboa PM; Viñuela JE; Sanz ML; Andreu C; Martínez A Clin Exp Allergy; 2009 Jul; 39(7):1088-98. PubMed ID: 19400901 [TBL] [Abstract][Full Text] [Related]
19. Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates with reduced allergenic activity. Najafi N; Hofer G; Gattinger P; Smiljkovic D; Blatt K; Selb R; Stoecklinger A; Keller W; Valent P; Niederberger V; Thalhamer J; Valenta R; Flicker S Sci Rep; 2019 Mar; 9(1):4006. PubMed ID: 30850635 [TBL] [Abstract][Full Text] [Related]
20. Induction of 'blocking' IgG antibodies during immunotherapy. Wachholz PA; Durham SR Clin Exp Allergy; 2003 Sep; 33(9):1171-4. PubMed ID: 12956735 [No Abstract] [Full Text] [Related] [Next] [New Search]